Cardiovascular Risk Assessment

Introduction to Cardiovascular Risk

• Elevated levels of homocysteine (>10 μmol/L) indicate increased risk for coronary artery disease, cerebrovascular disease, peripheral vascular disease, and deep venous thrombosis, according to the European Society of Cardiology 1
• Homocysteine is a sulfur-containing amino acid and a metabolite of methionine, with elevated levels being an independent risk factor for cardiovascular disease, stroke, and cognitive disorders, as stated by the European Society of Cardiology and the American Heart Association 2

Genetic Disorders and Homocysteine Metabolism

• Genetic defects in enzymes involved in homocysteine metabolism, such as cystathionine-synthase deficiency and methylenetetrahydrofolate reductase (MTHFR) deficiency or variants, may be indicated by elevated homocysteine levels, as suggested by the American Heart Association 3
• Plasma homocysteine measurement is generally more informative than MTHFR genetic testing, with levels >15 μmol/L considered diagnostic for hyperhomocysteinemia, according to the American Heart Association and the American College of Medical Genetics 4, 2

Cardiovascular Risk and Homocysteine Levels

• An increase in plasma homocysteine of 5 μmol/L increases coronary risk similar to an increase of 20 mg/dL in serum cholesterol, as reported by the American College of Cardiology 5
• High homocysteine levels predict poorer long-term cardiovascular prognosis in patients with established coronary disease, peripheral vascular disease, and end-stage kidney disease, according to the American Heart Association 5
• Elevated homocysteine levels begin to increase cardiovascular risk when fasting plasma concentrations exceed 10 μmol/L, according to the American Heart Association and the American College of Medical Genetics 4, 3

Stroke Risk and Homocysteine

• Elevated homocysteine is associated with increased stroke risk, with a 3 μmol/L decrease potentially reducing stroke risk by 24%, as suggested by the American Stroke Association 3
• Folate supplementation may reduce stroke risk, with a relative risk of 0.75 and a 95% confidence interval of 0.59 to 0.97, according to the American Heart Association 6

Cardiovascular Risk Stratification

• Homocysteine provides additional risk information beyond traditional risk factors, according to the European Society of Cardiology 1
• Both methylmalonic acid and homocysteine are more sensitive than serum B12 levels alone for detecting functional B12 deficiency, according to the American Academy of Physical Medicine and Rehabilitation 7
• Kidney disease, hypothyroidism, and hypovolemia can elevate both markers independently of vitamin status, as noted by the American Academy of Physical Medicine and Rehabilitation 7

Diagnosis and Measurement

• Measuring total plasma homocysteine (tHcy) requires precise sample collection and specialized laboratory analysis using HPLC or GC-MS techniques, as recommended by the European Society of Cardiology 2
• The following conditions can cause hyperhomocysteinemia:

1

Treatment and Management

• Reversal of the underlying cause is the best treatment for moderate hyperhomocysteinemia, as recommended by the European Society of Cardiology 1
• B vitamin supplementation can lower but often not normalize homocysteine levels in patients, with folic acid doses of 0.5-5 mg daily reducing homocysteine by approximately 25%, and vitamin B12 at 0.5 mg daily providing an additional 7% reduction, as recommended by the American College of Cardiology and the National Kidney Foundation 8, 9
• The following folate doses are recommended:

8, 10

• Smoking cessation is recommended for patients with elevated homocysteine levels, as stated by the American College of Cardiology 9
• Evaluating for kidney disease is crucial, as it may require higher doses of B vitamins, according to the National Kidney Foundation 8
• The American Heart Association/American Stroke Association suggests B-complex vitamins might be considered for prevention of ischemic stroke in patients with hyperhomocysteinemia (Class IIb; Level of Evidence B), as stated by the American Heart Association 11, 3

Special Considerations

• Decreased renal clearance contributes to elevated homocysteine levels in patients with chronic kidney disease, according to the American Stroke Association and the American Journal of Kidney Diseases 8, 3
• CKD has a high prevalence of hyperhomocysteinemia, with 85-100% of hemodialysis patients affected, and homocysteine levels increasing proportionally with CKD stage progression, as reported by the American Journal of Kidney Diseases 8
• Despite the effectiveness of B-vitamin supplementation in reducing homocysteine levels, multiple randomized controlled trials have failed to demonstrate that lowering homocysteine with B-vitamin supplementation reduces cardiovascular events or mortality, as reported by the American College of Cardiology 12
• For patients with kidney disease, the National Kidney Foundation recommends being cautious with high-potassium foods like leafy greens, and considering using oils from folate-rich foods (walnut, flaxseed, canola) which provide benefits without potassium concerns 8
• The National Kidney Foundation suggests including omega-3 fatty acid sources at least twice weekly, and avoiding saturated and trans fats 8